Antibodies emerge as key focus for Kyowa Kirin
This article was originally published in Scrip
Kyowa Hakko Kirin (KHK) is applying the technologies brought together by the merger of Kyowa Hakko and Kirin Pharma to an expanding pipeline of antibody products.
You may also be interested in...
Novartis is developing a new type of immunosuppressive agent, an anti-CD40 monoclonal antibody, which might allow organ transplants to last longer in recipients, reducing the pressure on transplant waiting lists and improving the long-term outlook for patients.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.